Review



th17 23 condition  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems th17 23 condition
    FIGURE 4. <t>Th17</t> cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Th17 23 Condition, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 333 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/th17 23 condition/product/R&D Systems
    Average 96 stars, based on 333 article reviews
    th17 23 condition - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways."

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    Journal: ImmunoHorizons

    doi: 10.4049/immunohorizons.2000008

    FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Figure Legend Snippet: FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Techniques Used:

    FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data
    Figure Legend Snippet: FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Techniques Used: Expressing, Control, Quantitative RT-PCR



    Similar Products

    th17 23 condition  (R&D Systems)
    96
    R&D Systems th17 23 condition
    FIGURE 4. <t>Th17</t> cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Th17 23 Condition, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/th17 23 condition/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    th17 23 condition - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Journal: ImmunoHorizons

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    doi: 10.4049/immunohorizons.2000008

    Figure Lengend Snippet: FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Article Snippet: The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.

    Techniques:

    FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Journal: ImmunoHorizons

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    doi: 10.4049/immunohorizons.2000008

    Figure Lengend Snippet: FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Article Snippet: The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.

    Techniques: Expressing, Control, Quantitative RT-PCR